Service Provider Agreement
February 04 2008 - 2:02AM
RNS Non-Regulatory
Medical Solutions PLC
04 February 2008
For further information, please contact:
Medical Solutions plc
Nick Ash
Managing Director
Tel: 0115 973 9010
www.medical-solutions.co.uk
Bishopsgate Communications Ltd
Nick Rome/Gemma O'Hara
Tel: 0207 562 3350
www.bishopsgatecommunications.com
4 February 2008
Medical Solutions plc
("Medical Solutions" or the "Company")
Medical Solutions becomes first UK commercial service provider of Illumina next
generation DNA sequencing and genotyping applications
The Board of Medical Solutions plc (LSE: MLS), a UK-based provider of expert,
quality DNA sequencing and genotyping services to the healthcare, pharma biotech
and life sciences research sectors, is pleased to announce that it is
implementing a new technology platform at its Nottingham laboratory that will
help to broaden the Company's offering and increase efficiencies.
Medical Solutions will become the UK's first commercial service provider for
these leading edge systems, which it will be sourcing from Illumina, Inc.
HIGHLIGHTS
* Medical Solutions to offer both Illumina's Genome Analyzer, a next
generation DNA sequencing system and Infinium whole genome genotyping on the
BeadStation platform;
* First commercial service provider of Illumina applications in the UK;
* Complete pipeline of histopathology to genomic services, including DNA
extraction, biobanking, whole genome amplification and DNA sequencing in
GLP, GCP and CPA accredited laboratories
Adoption of Illumina's DNA sequencing and genotyping platforms will complement
Medical Solutions' extensive portfolio of diagnostic and contract research
services ranging from cell and tissue to genomic analysis. This further
demonstrates the Company's commitment to be a market leader in the UK for the
provision of expert, quality laboratory services to the healthcare, pharma
biotech and life science research sectors.
Dr Tom Weaver, Commercial Director for Medical Solutions said, "We selected the
Illumina platforms because the data quality, reproducibility, flexibility and
breadth of applications are, in our opinion, the best in the industry. This
represents cutting edge technology capable of revealing an enormous volume of
genetic information. Customers have already expressed significant interest in
applications run on the Genome Analyzer and BeadStation platforms, and it is our
intention to develop strategic partnerships with these early adopters, enabling
them to take full advantage of the power of whole genome analysis by providing
high-quality data in an accredited quality laboratory environment. "
Dr. Weaver added, "Illumina DNA sequencing and genotyping platforms are also
capable of delivering analyses in the expanding field of personalised genomic
services."
"The addition of Illumina's Genome Analyzer and BeadStation platforms
demonstrates the level of commitment Medical Solutions has to its customers and
to providing them with leading-edge technologies that enable whole genome
analysis" said Karen Possemato, Director of Corporate Marketing at Illumina.
"Their added interest in becoming an Illumina CSPro further supports the value
Medical Solutions sees in Illumina's products and how this program can be a key
factor in their success."
- ends -
Notes to Editors:
About Medical Solutions
Medical Solutions is a leading provider of expert, quality services and products
to the healthcare, pharma biotech and life science research sectors. Its
Healthcare operations provide screening products and reference laboratory
diagnostic testing services for cancer and other diseases and additional
predictive testing for treatment optimisation for clinicians and patients.
Pharma Biotech Services offers support for early stage therapeutic development,
offering a "one-stop shop" from tissue pathology, immunohistochemistry,
sophisticated image analysis, biomarker determination and assay development to
pharmacogenomics including genotyping and gene expression analysis. The Life
Science Research services provide core laboratory research support from
conceptualization to implementation, calling upon a wide ranging of cutting-edge
technology platforms including and an online catalogue of biomolecular tools.
This incorporates DNA sequencing, whole genome amplification and a comprehensive
library of genomic reagents and clones including cDNA and RNAi.
The group has its headquarters in Nottingham, UK where it operates state of the
art reference laboratory facilities, with additional UK laboratory facilities in
Cambridge and Oxford. Medical Solutions is CPA, GLP and GCP accredited and is
licensed by the Human Tissue Authority.
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of next-generation life-science tools and integrated systems for the analysis of
genetic variation and biological function. Using our proprietary technologies,
we provide a comprehensive line of products and services that currently serve
the sequencing, genotyping, and gene expression markets, and we expect to enter
the market for molecular diagnostics. Our customers include leading genomic
research centers, pharmaceutical companies, academic institutions, clinical
research organizations, and biotechnology companies. Our tools provide
researchers around the world with the performance, throughput, cost
effectiveness, and flexibility necessary to perform the billions of genetic
tests needed to extract valuable medical information from advances in genomics
and proteomics. We believe this information will enable researchers to correlate
genetic variation and biological function, which will enhance drug discovery and
clinical research, allow diseases to be detected earlier, and permit better
choices of drugs for individual patients.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSFFMFSASEDE
Medical Solutions (LSE:MLS)
Historical Stock Chart
From May 2024 to Jun 2024
Medical Solutions (LSE:MLS)
Historical Stock Chart
From Jun 2023 to Jun 2024
